<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - DABIGATRAN ETEXILATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>DABIGATRAN ETEXILATE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following total knee replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;74 years</strong><br/>
                110 mg, to be taken 1&#8211;4 hours after surgery, followed by 220 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</li>
              <li class="dose adult"><strong>For adults 75 years and over</strong><br/>
                75 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following total hip replacement surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;74 years</strong><br/>
                110 mg, to be taken 1&#8211;4 hours after surgery, followed by 220 mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</li>
              <li class="dose adult"><strong>For adults 75 years and over</strong><br/>
                75 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of deep-vein thrombosis</span>,
                <span class="indication">Treatment of pulmonary embolism</span>,
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;74 years</strong><br/>
                150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</li>
              <li class="dose adult"><strong>For adults 75&#8211;79 years</strong><br/>
                110&#8211;150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</li>
              <li class="dose adult"><strong>For adults 80 years and over</strong><br/>
                110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of deep-vein thrombosis in patients with moderate renal impairment</span>,
                <span class="indication">Treatment of deep-vein thrombosis in patients at increased risk of bleeding</span>,
                <span class="indication">Treatment of pulmonary embolism in patients with moderate renal impairment</span>,
                <span class="indication">Treatment of pulmonary embolism in patients at increased risk of bleeding</span>,
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis in patients with moderate renal impairment</span>,
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism in patients with moderate renal impairment</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism in patients at increased risk of bleeding</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110&#8211;150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of deep-vein thrombosis in patients receiving concomitant treatment with verapamil</span>,
                <span class="indication">Treatment of pulmonary embolism in patients receiving concomitant treatment with verapamil</span>,
                <span class="indication">Prophylaxis of recurrent deep-vein thrombosis in patients receiving concomitant treatment with verapamil</span>,
                <span class="indication">Prophylaxis of recurrent pulmonary embolism in patients receiving concomitant treatment with verapamil</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults 18&#8211;74 years</strong><br/>
                150 mg twice daily.</li>
              <li class="dose adult"><strong>For adults 75&#8211;79 years</strong><br/>
                110&#8211;150 mg twice daily.</li>
              <li class="dose adult"><strong>For adults 80 years and over</strong><br/>
                110 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients at increased risk of bleeding</span>,
                <span class="indication">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients with moderate renal impairment</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                110&#8211;150 mg twice daily.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>For information on changing from, or to, other anticoagulants, consult product literature.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless essential&#8212;toxicity in <i>animal </i>studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Avoid in severe liver disease, especially if prothrombin time already prolonged.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery</i>, reduce initial dose to 75&#8239;mg and subsequent doses to 150&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/ minute; reduce dose to 75&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/minute and patient receiving concomitant treatment with verapamil.</p><p>For <i>treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation,</i> consider reduced dose of 110&#8239;mg twice daily if creatinine clearance 30&#8211;50&#8239;mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Active bleeding</li>
            <li>do not use as anticoagulant for prosthetic heart valve</li>
            <li>malignant neoplasms</li>
            <li>oesophageal varices</li>
            <li>recent brain surgery</li>
            <li>recent gastro-intestinal ulcer</li>
            <li>recent intracranial haemorrhage</li>
            <li>recent ophthalmic surgery</li>
            <li>recent spine surgery</li>
            <li>significant risk of major bleeding</li>
            <li>vascular aneurysm</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, anaemia, diarrhoea, dyspepsia, haemorrhage, nausea,
              </p>
              <p>
                <strong>uncommon:</strong> Dysphagia, gastro-intestinal ulcer, gastro-oesophageal reflux, hepatobiliary disorders, oesophagitis, thrombocytopenia, vomiting,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA157</h3>
              <p outputclass="title">Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008)</p> <p>Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p><xref format="html" href="http://www.nice.org.uk/TA157">www.nice.org.uk/TA157</xref>
                <a href="http://www.nice.org.uk/TA157" target="_blank">www.nice.org.uk/TA157</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA249</h3>
              <p outputclass="title">Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012)</p> <p>Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors:</p> <ul> <li>previous stroke, transient ischaemic attack, or systemic embolism</li> <li>left ventricular ejection fraction &lt;40%</li> <li>symptomatic heart failure</li> <li>age &#8805;75 years</li> <li>age &#8805;65 years in patients with diabetes mellitus, coronary artery disease, or hypertension</li> </ul> <p>The risks and benefits of dabigatran compared to warfarin should be discussed with the patient.</p><xref format="html" href="http://www.nice.org.uk/TA249">www.nice.org.uk/TA249</xref>
                <a href="http://www.nice.org.uk/TA249" target="_blank">www.nice.org.uk/TA249</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA327</h3>
              <p outputclass="title">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism (December 2014)</p> <p>Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.</p><xref format="html" href="http://www.nice.org.uk/TA327">www.nice.org.uk/TA327</xref>
                <a href="http://www.nice.org.uk/TA327" target="_blank">www.nice.org.uk/TA327</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;give initial dose at least 2 hours after catheter removal and monitor neurological signs)
          </li>
          <li>
            bacterial endocarditis
          </li>
          <li>
            bleeding disorders
          </li>
          <li>
            body-weight less than 50&#8239;kg
          </li>
          <li>
            elderly
          </li>
          <li>
            gastritis
          </li>
          <li>
            gastro-oesophageal reflux
          </li>
          <li>
            oesophagitis
          </li>
          <li>
            recent biopsy
          </li>
          <li>
            recent major trauma
          </li>
          <li>
            thrombocytopenia
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p><p>No routine anticoagulant monitoring required (INR tests are unreliable).</p><p>Assess renal function (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.</p>
            </section>
      </section>


      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of DABIGATRAN ETEXILATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77319"><a href="../medicinalForm/PHP77319.html" data-target="#PHP77319" data-action="load">Capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
